Bioventus Inc

Bioventus Inc

BVS · NASDAQ · Healthcare / Medical Devices

10.66USD-0.20 (-1.84%)

Price History

Full chart

Market Stats

Previous Close10.86
Open11.00
Day Range10.64 – 11.00
52-Week Range6.37 – 15.89
Volume650.63K
Market Cap923.49M
P/E (TTM)17.56
Forward P/E14.79
EPS0.77
Dividend Yield0.00%
Beta0.65
50-Day Avg13.44
200-Day Avg10.09

About

Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Robert E. Claypoole
  • Employees950
  • Headquarters4721 Emperor Boulevard, Durham, NC, United States, 27703, USA
  • Websitehttps://www.bioventus.com

Leadership

  • Mr. Robert E. ClaypoolePresident, CEO & Director · b. 1972
  • Mr. Mark L. SingletonSenior VP & CFO · b. 1969
  • Mr. Anthony D'Adamio J.D.Senior VP, General Counsel & Corporate Secretary · b. 1961
  • Mr. Mike Crowe B.S., M.B.A.Senior Vice President of Operations
  • Mr. David CrawfordVice President of Investor Relations & Treasurer
  • Ms. Katrina J. Church J.D.Senior VP & Chief Compliance Officer · b. 1962
  • Ms. Helen LeupoldSenior VP & Chief Human Resources Officer
  • Mr. Dave VennerSenior VP & GM of Surgical

Financials

Income Statement

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue232.38M242.89M253.65M274.50M292.06M319.18M340.14M321.16M430.90M512.12M512.35M573.28M568.09M
Growth (%)-+4.53%+4.43%+8.22%+6.40%+9.29%+6.57%-5.58%+34.17%+18.85%+0.04%+11.89%-0.91%
Cost of Revenue71.37M74.61M74.34M91.39M92.10M84.17M90.94M87.64M128.19M181.04M184.15M185.05M185.66M
Gross Profit161.00M168.28M179.31M183.11M199.96M235.01M249.21M233.52M302.71M331.08M328.19M388.23M382.43M
Gross Margin69.29%69.28%70.69%66.71%68.47%73.63%73.27%72.71%70.25%64.65%64.06%67.72%67.32%
Operating Expense169.07M168.26M195.90M168.22M172.94M209.50M218.01M212.28M290.64M498.31M409.92M400.20M323.88M
Operating Income-8.07M20.00K-16.59M14.89M27.02M25.50M31.19M21.24M12.06M-167.23M-81.72M-11.98M58.55M
Operating Margin-3.47%0.01%-6.54%5.42%9.25%7.99%9.17%6.61%2.80%-32.66%-15.95%-2.09%10.31%
EBITDA15.68M29.30M38.63M44.05M59.85M54.52M61.58M54.31M45.48M-121.61M-23.07M39.22M99.21M
EBITDA Margin6.75%12.06%15.23%16.05%20.49%17.08%18.11%16.91%10.55%-23.75%-4.50%6.84%17.46%
Net Income-22.37M-12.90M-34.11M-17.95M-1.64M-12.21M6.85M16.41M19.38M-158.70M-156.23M-33.54M22.73M
Net Income Margin-9.63%-5.31%-13.45%-6.54%-0.56%-3.82%2.01%5.11%4.50%-30.99%-30.49%-5.85%4.00%
R&D10.94M9.46M14.75M7.90M8.10M8.10M11.05M11.20M19.04M23.85M13.45M13.64M12.11M
R&D as % of Total Revenue4.71%3.90%5.81%2.88%2.77%2.54%3.25%3.49%4.42%4.66%2.62%2.38%2.13%
Interest Expense11.46M11.97M14.23M15.94M18.90M19.17M21.58M9.75M1.11M12.02M40.68M38.79M26.49M
Interest Expense % of Total Revenue4.93%4.93%5.61%5.81%6.47%6.01%6.34%3.04%0.26%2.35%7.94%6.77%4.66%

Balance Sheet

Currency: USD2013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets-430.42M487.35M--442.72M472.41M494.47M1.23B1.37B810.91M727.96M683.56M
Total Liabilities-252.93M295.01M--297.46M326.79M350.31M692.07M960.43M589.79M542.35M455.11M
Total Equity-177.49M192.34M--145.27M142.98M142.24M458.92M325.24M173.59M147.94M184.10M
Cash-15.77M4.95M--42.77M64.52M86.84M43.93M30.19M36.96M41.58M51.24M
Total Debt-170.98M196.51M--194.83M197.97M188.38M357.68M418.07M394.85M335.63M311.35M
Net Debt-155.20M191.56M--152.05M133.44M101.54M313.75M387.88M357.88M294.05M260.11M

Cash Flow

Currency: USD2013-12-312014-12-312015-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow2.75M15.11M18.92M45.19M40.71M71.80M22.99M-13.54M15.34M38.80M73.98M
Investing Cash Flow-11.00M-31.38M-60.19M-6.10M-7.91M-20.50M-283.76M-116.44M15.81M22.96M-3.25M
Financing Cash Flow6.80M-6.64M31.25M-13.26M-10.95M-29.57M273.37M62.08M-26.65M-54.58M-61.44M
Capital Expenditure6.36M20.83M7.44M6.06M8.34M20.67M7.37M1.48M7.36M1.01M2.56M
Free Cash Flow-3.61M-5.72M11.48M39.13M32.37M51.13M15.62M-15.02M7.98M37.79M71.41M
Dividends Paid2.50M2.40M1.02M7.85M9.14M19.89M367.00K9.14M---
FCF to OCF-131.21%-37.86%60.67%86.59%79.51%71.21%67.94%110.92%52.02%97.41%96.54%
Dividend Paid to FCF-69.34%-41.93%8.85%20.05%28.23%38.90%2.35%-60.85%---

Earnings

Report DateOct 6, 2020Mar 25, 2021May 12, 2021Aug 10, 2021Nov 9, 2021Mar 10, 2022May 10, 2022Aug 11, 2022Nov 8, 2022Mar 31, 2023May 16, 2023Aug 8, 2023Nov 7, 2023Mar 12, 2024May 7, 2024Aug 6, 2024Nov 5, 2024Mar 10, 2025May 6, 2025Aug 6, 2025Nov 4, 2025Mar 17, 2026May 6, 2026Aug 5, 2026Nov 3, 2026
EPS Estimate0.000.230.100.140.150.180.050.160.120.05-0.150.03-0.020.02-0.070.070.020.090.020.200.120.200.070.220.17
EPS Actual0.022.320.150.160.250.260.040.100.08-0.06-0.260.140.050.070.070.190.060.150.080.210.150.240.150.22-
Surprise-908.70%50.00%14.29%66.67%44.44%-20.00%-37.50%-33.33%-220.00%-73.33%366.67%350.00%250.00%200.00%171.43%200.00%76.47%300.00%5.00%25.00%17.53%114.29%0.00%-
Timing-After-hoursAfter-hoursAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-market-Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap923.49M
Enterprise Value1.15B
Trailing P/E17.56
Forward P/E14.79
PEG Ratio1.53
Price / Sales1.59
Price / Book4.07
EPS0.77
Book Value3.35
Revenue (TTM)581.85M
Gross Profit (TTM)399.45M
EBITDA80.14M
Profit Margin9.36%
Operating Margin12.23%
Return on Equity25.68%
Return on Assets5.49%
Shares Outstanding68.31M
Shares Float34.30M
Beta0.65
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Analyst Ratings

Buy
Based on 3 analystsTarget 17.60
  • Strong Buy
    2
  • Hold
    1

Ownership Breakdown

Institutions
83.08%
Insiders
11.65%
Retail / Other
5.27%

Top Institutional Holders

  • Essex Woodlands Health Ventures
    13.02M19.06%
  • Juniper Investment Co, LLC
    6.94M10.16%
  • Nantahala Capital Management, LLC
    6.12M8.96%
  • BlackRock Inc
    3.13M4.59%
  • Vanguard Capital Management, LLC
    1.71M2.51%
  • Royce & Associates, LP
    1.54M2.26%
  • American Century Companies Inc
    1.35M1.98%
  • Geode Capital Management, LLC
    1.17M1.71%
  • Dimensional Fund Advisors, Inc.
    1.13M1.65%
  • State Street Corp
    988.37K1.45%
  • Vanguard Portfolio Management, LLC
    973.00K1.42%
  • Hillsdale Investment Management Inc.
    907.74K1.33%
  • Engine Capital Management LP
    900.56K1.32%
  • Wellington Management Company LLP
    748.36K1.10%

Top Fund Holders

  • Avantis US Small Cap Value ETF
    1.52M2.23%
  • Brown Advisory Small-Cap Fdmtl Val Inv
    1.25M1.83%
  • iShares Russell 2000 ETF
    1.23M1.81%
  • Vanguard MStar Total Stk Mkt Idx Invest
    1.16M1.70%
  • FTGF RY US SmCp Opp A USD Dis(A)
    927.00K1.36%
  • Royce Small-Cap Opportunity Invmt
    858.74K1.26%